- Home
- AUGO vs ARQT Comparison
AUGO vs ARQT Comparison
Compare AUGO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUGO
- ARQT
- Stock Information
- Founded
- AUGO 1946
- ARQT 2016
- Country
- AUGO United States
- ARQT United States
- Employees
- AUGO N/A
- ARQT N/A
- Industry
- AUGO
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- AUGO
- ARQT Health Care
- Exchange
- AUGO Nasdaq
- ARQT Nasdaq
- Market Cap
- AUGO 1.8B
- ARQT 1.7B
- IPO Year
- AUGO N/A
- ARQT 2020
- Fundamental
- Price
- AUGO $28.04
- ARQT $15.98
- Analyst Decision
- AUGO
- ARQT Strong Buy
- Analyst Count
- AUGO 0
- ARQT 7
- Target Price
- AUGO N/A
- ARQT $19.00
- AVG Volume (30 Days)
- AUGO 207.9K
- ARQT 1.7M
- Earning Date
- AUGO 08-05-2025
- ARQT 08-06-2025
- Dividend Yield
- AUGO 4.42%
- ARQT N/A
- EPS Growth
- AUGO N/A
- ARQT N/A
- EPS
- AUGO N/A
- ARQT N/A
- Revenue
- AUGO $679,914,000.00
- ARQT $263,464,999.00
- Revenue This Year
- AUGO $23.75
- ARQT $61.83
- Revenue Next Year
- AUGO $12.09
- ARQT $36.55
- P/E Ratio
- AUGO N/A
- ARQT N/A
- Revenue Growth
- AUGO 35.59
- ARQT 99.50
- 52 Week Low
- AUGO $22.24
- ARQT $8.03
- 52 Week High
- AUGO $28.14
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- AUGO N/A
- ARQT 60.54
- Support Level
- AUGO N/A
- ARQT $13.70
- Resistance Level
- AUGO N/A
- ARQT $16.39
- Average True Range (ATR)
- AUGO 0.00
- ARQT 0.88
- MACD
- AUGO 0.00
- ARQT 0.07
- Stochastic Oscillator
- AUGO 0.00
- ARQT 84.79
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.